Azenta, Inc. (AZTA) Income Statement

The 12.0% growth in 2026Q3 marks a sharp acceleration from the low-single-digit or negative growth rates seen in the prior eight quarters, with 2025Q4 at 5.7% and 2025Q3 at -0.2%. This suggests that the recurring revenue base, particularly in Life Sciences Services, is gaining traction, possibly offsetting continued softness in capital equipment sales. However, the sustainability of this growth is uncertain given the CEO's commentary on an 'uneven and challenging market backdrop,' and the modest improvement in North America Multiomics may not be broad-based.

The gross margin has hovered between 42.8% and 47.1% over the period, with the latest quarter at 44.9%, slightly below the 45.5% average. This stability suggests that the company has been able to maintain pricing in its premium sample management and genomics services, even as volumes fluctuate. The slight dip in 2026Q2 to 42.8% may reflect mix shifts or temporary cost pressures, but the recovery in 2026Q3 indicates that the underlying margin structure is intact. Investors should monitor whether the 'Ascend' transformation program can drive gross margin expansion toward the higher end of the range.

The operating margin improved from -10.6% in 2026Q2 to -2.6% in 2026Q3, but the company has only achieved positive operating income in two of the last ten quarters (2025Q4 and 2024Q4). This suggests that the high fixed-cost base, including depreciation and labor for genomic services, is not yet being fully absorbed by current revenue levels. The 'Ascend' program aims to streamline costs, but the lack of consistent operating leverage indicates that significant revenue growth or cost reductions are needed to achieve sustainable profitability.

SG&A has ranged from $54.9M to $67.9M, with no clear downward trend despite the 'Ascend' transformation program. In 2026Q3, SG&A was $67.2M, up from $61.1M in 2025Q4, even as revenue grew. This suggests that the company has not yet achieved meaningful overhead efficiency. R&D spending has been relatively stable at $7-9M per quarter, indicating a consistent investment in innovation. The lack of SG&A discipline is a key reason why operating margins remain negative, and investors should monitor whether management can reduce SG&A as a percentage of revenue as part of the 'Ascend' program.

The last ten quarters show a clear pattern of declining revenue from 2024Q2 through 2025Q3, with growth turning positive only in 2025Q4 and accelerating in 2026Q3. This inflection appears to be driven by strength in recurring revenue businesses, as noted in the earnings beat. However, the mixed guidance and CEO's cautious commentary suggest that this may not be a broad-based recovery. The lasting impact of this inflection will depend on whether the company can sustain double-digit growth and translate it into positive operating income, which has been elusive.